BioRestorative Therapies, Inc. Common Stock (NV)
Veridion Score
Composite trend over time
Why is BRTX moving today?
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for BRTX.
BRTX insider activity
BioRestorative Therapies, Inc. Common Stock (NV)
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for BRTX.
BRTX contract awards, year to date.
Public federal awards linked to this ticker.
BRTX lobbying filings, year to date.
Registered lobbying filings matched to BioRestorative Therapies, Inc. Common Stock (NV).